Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2020

Open Access 01-07-2020 | Breast Cancer | Special Article

Annual report of the Japanese Breast Cancer Society registry for 2016

Authors: Makoto Kubo, Hiraku Kumamaru, Urara Isozumi, Minoru Miyashita, Masayuki Nagahashi, Takayuki Kadoya, Yasuyuki Kojima, Kenjiro Aogi, Naoki Hayashi, Kenji Tamura, Sota Asaga, Naoki Niikura, Etsuyo Ogo, Kotaro Iijima, Kenta Tanakura, Masayuki Yoshida, Hiroaki Miyata, Yutaka Yamamoto, Shigeru Imoto, Hiromitsu Jinno

Published in: Breast Cancer | Issue 4/2020

Login to get access

Abstract

The Japanese Breast Cancer Society (JBCS) registry began data collection in 1975, and it was integrated into National Clinical Database in 2012. As of 2016, the JBCS registry contains records of 656,896 breast cancer patients from more than 1400 hospitals throughout Japan. In the 2016 registration, the number of institutes involved was 1422, and the total number of patients was 95,870. We herein present the summary of the annual data of the JBCS registry collected in 2016. We analyzed the demographic and clinicopathologic characteristics of registered breast cancer patients from various angles. Especially, we examined the registrations on family history, menstruation, onset age, body mass index according to age, nodal status based on tumor size and subtype, and proportion based on ER, PgR, and HER2 status. This report based on the JBCS registry would support clinical management for breast cancer patients and clinical study in the near future.
Literature
1.
Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer. 2015;22:235–44.CrossRef
2.
Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley; 2010. p. 131–141.
3.
The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 17th ed. Tokyo: Kanehara Shuppan; 2012.
4.
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours of the breast. 4th ed. Lyon: IARC Press; 2012.
5.
6.
7.
Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;27:1389–99.
Metadata
Title
Annual report of the Japanese Breast Cancer Society registry for 2016
Authors
Makoto Kubo
Hiraku Kumamaru
Urara Isozumi
Minoru Miyashita
Masayuki Nagahashi
Takayuki Kadoya
Yasuyuki Kojima
Kenjiro Aogi
Naoki Hayashi
Kenji Tamura
Sota Asaga
Naoki Niikura
Etsuyo Ogo
Kotaro Iijima
Kenta Tanakura
Masayuki Yoshida
Hiroaki Miyata
Yutaka Yamamoto
Shigeru Imoto
Hiromitsu Jinno
Publication date
01-07-2020
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2020
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-020-01081-4

Other articles of this Issue 4/2020

Breast Cancer 4/2020 Go to the issue

Correction

Correction to: Histological classification of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition)

Original Article

Immediate one-stage implant-based breast reconstruction without the use of acellular dermal matrix in Japanese breast cancer patients

Original Article

Epidemiology and biological characteristics of male breast cancer in Italy

Original Article

Higher dietary total antioxidant capacity is not associated with risk of breast cancer in Iranian women

Original Article

The apatinib inhibits breast cancer cell line MDA-MB-231 in vitro by inducing apoptosis, cell cycle arrest, and regulating nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways

Original Article

Comparative effect of sodium butyrate and sodium propionate on proliferation, cell cycle and apoptosis in human breast cancer cells MCF-7
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits